The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits;
Age ≥18 years, male or female;
Patients with advanced malignant tumors confirmed pathologically;
Failure of adequate standard treatment, or no effective standard treatment;
Subjects had cancerous meningitis or untreated central nervous system metastases;
Subjects had severe cardiovascular and cerebrovascular diseases;
There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion);
Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia;